心血管

专访Roxana Mehran教授

作者:许茂怡、张致媛 来源:中国医学论坛报今日循环 日期:2015-03-23
导读

         CIT可谓中国乃至亚太地区最好的会议,其参会人数量庞大、重视年轻一代的培养、且展示了很多在患者诊疗方面的巨大进展。我对有关生物可吸收支架(BRS)和经导管主动脉置换术(TAVR)的报告也非常感兴趣。

关键字:  CIT2015 | 海外专家访谈 

  Roxana Mehran教授

  这是我第8次参加CIT。对我来说CIT已经成为不容错过的会议,一是因为其精彩的学术内容,二是因为每年同道们都相聚在此共议学术。我们知道,中国介入心脏病领域飞速发展,人们辛勤工作,开展具备高质量数据的试验。许多中国原创研究正在影响世界,例如China PEACE研究和BRIGHT研究。

  CIT可谓中国乃至亚太地区最好的会议,其参会人数量庞大、重视年轻一代的培养、且展示了很多在患者诊疗方面的巨大进展。我相信CIT会吸引越来越多的国际关注——如果你错过了CIT,就意味着错过太多。会议组织者非常重视有关临床研究的教育和基础建设。我期待今年的CIT继续其重视教育的传统,促进中国和全球的学术发展。

  此外,我对有关生物可吸收支架(BRS)和经导管主动脉置换术(TAVR)的报告也非常感兴趣。

  This is my 8th time attending CIT. It is absolutely a must for me to come to this meeting, because of its incredible scientific content, as well as the fact that my colleagues are gathering here every year. We know that China is highly progressive in interventional cardiology. People are working hard, doing excellent trials with data of good quality. There are so many studies of international influence from China now, such as the China PEACE study and the BRIGHT study.

  CIT is the top meeting in China, or even in the Asia Pacific area, if not the world, because of its tremendous number of attendees, great interest in educating the younger generation and demonstration of huge improvements inpatient care. I am sure that it will attract more and more international attention, as when you miss the CIT, you missed a lot.

  The organizers are concerned about including enough teaching and infrastructure about clinical research in this meeting. I am expecting this years’ CIT to continue the tradition of education and to promote research both in China and around the world. Except these, I am particularly interested in hearing from China about BRS and TAVR.

分享:

相关文章

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像

京ICP证120392号  京公网安备110105007198  京ICP备10215607号-1  (京)网药械信息备字(2022)第00160号
//站内统计 //百度统计 //谷歌统计 //站长统计
*我要反馈: 姓    名: 邮    箱:
Baidu
map